X4 Pharmaceuticals (NASDAQ:XFOR) Announces Earnings Results

X4 Pharmaceuticals (NASDAQ:XFOR) issued its quarterly earnings data on Thursday. The company reported ($0.13) EPS for the quarter, beating the consensus estimate of ($0.18) by $0.05, Zacks reports. X4 Pharmaceuticals had a negative return on equity of 94.90% and a negative net margin of 1,106.30%.

X4 Pharmaceuticals Trading Up 0.5%

Shares of XFOR stock traded up $0.02 during trading on Thursday, hitting $4.17. 447,777 shares of the stock traded hands, compared to its average volume of 545,007. X4 Pharmaceuticals has a 52-week low of $1.35 and a 52-week high of $4.83. The firm has a market capitalization of $393.31 million, a P/E ratio of -0.92 and a beta of 0.37. The firm’s fifty day moving average price is $4.02 and its 200-day moving average price is $3.94. The company has a debt-to-equity ratio of 0.45, a current ratio of 10.18 and a quick ratio of 9.98.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on XFOR. Leerink Partners began coverage on shares of X4 Pharmaceuticals in a research note on Tuesday, June 2nd. They issued an “outperform” rating and a $12.00 price target on the stock. Wells Fargo & Company initiated coverage on shares of X4 Pharmaceuticals in a report on Friday, July 10th. They set an “overweight” rating and a $11.00 price objective on the stock. Finally, Weiss Ratings raised shares of X4 Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, July 28th. Five equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, X4 Pharmaceuticals currently has an average rating of “Moderate Buy” and an average target price of $9.70.

Insider Buying and Selling at X4 Pharmaceuticals

In other X4 Pharmaceuticals news, CFO David Kirske sold 8,543 shares of X4 Pharmaceuticals stock in a transaction dated Tuesday, June 30th. The shares were sold at an average price of $4.26, for a total transaction of $36,393.18. Following the completion of the sale, the chief financial officer directly owned 167,750 shares in the company, valued at $714,615. This trade represents a 4.85% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 1.13% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. Bank of America Corp DE boosted its position in X4 Pharmaceuticals by 20.3% in the 4th quarter. Bank of America Corp DE now owns 133,502 shares of the company’s stock valued at $98,000 after buying an additional 22,485 shares during the period. Rhumbline Advisers boosted its holdings in X4 Pharmaceuticals by 5.4% in the first quarter. Rhumbline Advisers now owns 188,415 shares of the company’s stock valued at $44,000 after purchasing an additional 9,690 shares during the period. Jane Street Group LLC grew its stake in X4 Pharmaceuticals by 112.5% during the 2nd quarter. Jane Street Group LLC now owns 97,344 shares of the company’s stock worth $185,000 after purchasing an additional 51,544 shares in the last quarter. Vanguard Group Inc. grew its stake in X4 Pharmaceuticals by 77.0% during the 3rd quarter. Vanguard Group Inc. now owns 410,485 shares of the company’s stock worth $1,404,000 after purchasing an additional 178,593 shares in the last quarter. Finally, Two Sigma Investments LP purchased a new stake in X4 Pharmaceuticals during the 3rd quarter worth about $47,000. Institutional investors and hedge funds own 72.03% of the company’s stock.

X4 Pharmaceuticals Company Profile

X4 Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapies targeting the C-X-C chemokine receptor type 4 (CXCR4) for the treatment of rare immunological diseases and oncology indications. The company’s lead asset, mavorixafor, is an orally administered, selective small-molecule CXCR4 antagonist designed to mobilize white blood cells and enhance immune function, with a primary focus on WHIM syndrome, a rare congenital immunodeficiency.

Beyond its WHIM syndrome program, X4 is advancing mavorixafor in clinical trials for additional hematologic and solid tumor settings—such as Waldenström’s macroglobulinemia and chronic lymphocytic leukemia—where modulation of the CXCR4 pathway may improve patient outcomes.